Does Medicare Advantage Cover Farxiga (Dapagliflozin)?

How Medicare Advantage Part D Covers Farxiga

Farxiga (dapagliflozin) holds three distinct FDA approvals, and each one carries separate coverage implications under Medicare Advantage. The drug earned approval for type 2 diabetes in 2014, for heart failure with reduced ejection fraction in 2020, and for chronic kidney disease in 2021 [1]. These three indications form the basis of Part D coverage determinations.

Medicare Advantage plans operate under CMS (Centers for Medicare & Medicaid Services) formulary guidelines, which require Part D sponsors to cover at least two drugs per therapeutic class [2]. SGLT2 inhibitors like dapagliflozin and empagliflozin both appear in the antidiabetic and cardiovascular therapeutic classes. Because Farxiga now spans multiple CMS-recognized classes, it appears on the majority of Medicare Advantage formularies nationwide.

A 2023 analysis published in JAMA Network Open found that SGLT2 inhibitor coverage among Part D plans increased from 78% in 2019 to 94% in 2022 after the heart failure and CKD indications were approved [3]. The expansion of FDA-labeled uses effectively pushed more plans to include these drugs as medically necessary rather than optional formulary additions.

Your specific plan determines whether Farxiga sits on Tier 3 (preferred brand, lower copay) or Tier 4 (non-preferred brand, higher copay). Plans affiliated with larger pharmacy benefit managers like CVS Caremark, Express Scripts, and OptumRx tend to negotiate different tier placements based on rebate agreements with AstraZeneca. Checking your plan's formulary lookup tool or calling the number on your member card is the fastest way to confirm tier status.

Prior Authorization Requirements for Farxiga

Prior authorization is the most common barrier between a prescription and coverage. Most Medicare Advantage plans require it for Farxiga, but approval rates for on-label use are consistently above 85% according to CMS Part D claims data [4].

The standard criteria a plan will verify include: a confirmed diagnosis of type 2 diabetes, HFrEF (NYHA Class II to IV), or CKD with eGFR between 25 and 75 mL/min/1.73 m²; documentation that the prescriber is an appropriate specialist or primary care physician; and evidence that the patient does not have type 1 diabetes or a history of diabetic ketoacidosis. Some plans also require an HbA1c value on file for diabetes-related requests.

Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, noted in a 2023 Diabetes Care editorial: "SGLT2 inhibitors have moved beyond glucose-lowering agents. Their cardiorenal benefits make them first-line therapy for patients with established cardiovascular or kidney disease, regardless of diabetes status" [5]. This clinical consensus has pushed many Medicare Advantage plans to simplify their PA criteria for the heart failure and CKD indications.

Your prescriber's office typically handles PA submission electronically through CoverMyMeds or a similar platform. Turnaround is 24 to 72 hours for standard requests. Expedited requests, filed when delay could cause serious harm, must receive a decision within 24 hours under CMS regulations [6].

Step Therapy: Will Your Plan Make You Try Other Drugs First

Step therapy protocols require patients to try (and fail) a less expensive medication before the plan approves a higher-cost alternative. For Farxiga prescribed for type 2 diabetes, some Medicare Advantage plans mandate a trial of metformin first. This requirement aligns with ADA Standards of Care, which recommend metformin as initial pharmacotherapy for most patients with type 2 diabetes [5].

The step therapy picture changes for heart failure and CKD. Few plans impose step therapy when Farxiga is prescribed specifically for heart failure with reduced ejection fraction. The DAPA-HF trial (N=4,744) demonstrated a 26% relative risk reduction in the composite of worsening heart failure or cardiovascular death with dapagliflozin versus placebo, establishing the drug as a foundational therapy alongside ACE inhibitors, beta-blockers, and mineralocorticoid receptor antagonists [7]. The 2022 AHA/ACC/HFSA heart failure guidelines gave SGLT2 inhibitors a Class I recommendation for HFrEF, meaning withholding the drug class requires clinical justification [8].

For CKD, the DAPA-CKD trial (N=4,304) showed a 39% reduction in the composite of sustained decline in eGFR of at least 50%, end-stage kidney disease, or renal or cardiovascular death [9]. KDIGO 2024 guidelines recommend SGLT2 inhibitors for patients with CKD and eGFR ≥20 mL/min/1.73 m², with or without diabetes [10]. Plans that impose step therapy for the CKD indication typically accept documentation of guideline-concordant prescribing as sufficient to bypass the requirement.

If your plan requires step therapy and you have already tried the required medications through a previous insurer or before enrolling in Medicare, ask your prescriber to submit records of those prior trials. CMS rules prohibit plans from requiring patients to re-fail a medication they have already tried [6].

Formulary Tier Placement and What You Will Pay

The amount you pay out of pocket for Farxiga depends on your plan's tier structure and which Part D coverage phase you are in. Understanding the four phases of Part D coverage matters.

Initial Deductible Phase. In 2026, the standard Part D deductible is $590. During this phase, you pay the full negotiated price for Farxiga until you meet the deductible. Some Medicare Advantage plans waive the deductible for preferred brand drugs.

Initial Coverage Phase. After meeting the deductible, you enter the initial coverage phase. For a Tier 3 drug, typical copays range from $30 to $50 per month. Tier 4 placement usually means $80 to $150, or a 25% to 33% coinsurance rate. At Farxiga's list price of approximately $620 per month, 25% coinsurance translates to roughly $155 before any supplemental coverage [11].

Coverage Gap (Donut Hole). The Inflation Reduction Act of 2022 capped out-of-pocket costs in the coverage gap. Starting in 2025, Part D enrollees pay no more than $2 to 000 in total annual out-of-pocket drug costs, which means the former "donut hole" penalty no longer applies [12]. This $2,000 cap is a hard ceiling. Once reached, you enter catastrophic coverage for the rest of the year.

Catastrophic Phase. After hitting the $2,000 cap, you pay $0 for covered Part D drugs for the remainder of the calendar year [12].

For a Medicare Advantage enrollee taking only Farxiga at Tier 3 with a $47 monthly copay, the $2,000 annual cap would be reached around month 9 of the plan year (accounting for the deductible phase). The remaining three months would be cost-free.

Why Farxiga Is Not Covered for Weight Loss

CMS maintains a statutory exclusion for drugs prescribed solely for weight loss under Part D [13]. Farxiga does not carry an FDA-approved weight loss indication, and its effect on body weight is modest. In the DECLARE-TIMI 58 trial (N=17,160), dapagliflozin produced an average weight reduction of 1.8 kg (approximately 4 lbs) compared to placebo over a median 4.2-year follow-up [14]. That is not a clinically meaningful weight loss outcome by obesity medicine standards.

Even after CMS expanded Part D coverage to include Wegovy (semaglutide 2.4 mg) for cardiovascular risk reduction in patients with established atherosclerotic cardiovascular disease following the SELECT trial results, SGLT2 inhibitors remain excluded from this pathway [15]. The distinction is clear: Wegovy holds a specific FDA-approved indication for reducing major adverse cardiovascular events in obese adults with established cardiovascular disease, while Farxiga's cardiovascular benefits are labeled under heart failure and CKD.

If a prescriber writes Farxiga with a primary diagnosis code for obesity (ICD-10 E66.x), the claim will almost certainly be rejected. Coverage requires an appropriate primary diagnosis: E11.x for type 2 diabetes, I50.x for heart failure, or N18.x for chronic kidney disease.

How to Appeal a Medicare Advantage Denial for Farxiga

A denial is not the final word. Medicare Advantage appeals follow a structured five-level process, and CMS data shows that approximately 75% of Part D appeals that reach an independent review are decided in the beneficiary's favor [16].

Level 1: Plan Redetermination. Your first step is an internal appeal to the plan itself. You or your prescriber must file within 60 days of the denial notice. The plan has 7 days for standard requests and 72 hours for expedited requests. Include the specific clinical rationale, relevant lab values, prior medication trials, and guideline references (ADA Standards of Care, AHA/ACC heart failure guidelines, or KDIGO CKD guidelines).

Level 2: Independent Review Entity (IRE). If the plan upholds the denial, the case automatically forwards to MAXIMUS Federal Services, the CMS-contracted IRE. MAXIMUS reviews the clinical evidence independently. Their decision is binding on the plan. The review takes up to 7 days for standard and 72 hours for expedited cases.

Level 3: Office of Medicare Hearings and Appeals (OMHA). If the amount in controversy meets the threshold ($220 in 2026), you can request an Administrative Law Judge hearing. This step is rarely needed for single-drug coverage disputes.

Levels 4 and 5. The Medicare Appeals Council and federal district court represent the final appellate stages. These are reserved for extraordinary circumstances.

Dr. G. Caleb Alexander, Professor of Epidemiology at Johns Hopkins Bloomberg School of Public Health, observed in a 2022 Annals of Internal Medicine commentary: "The prior authorization burden for evidence-based cardiovascular therapies creates a paradox where the drugs with the strongest outcomes data face the most administrative friction" [17]. His point is supported by a CMS Office of Inspector General report finding that Medicare Advantage organizations overturned 75% of their own denials on appeal, suggesting many initial denials lack adequate clinical justification [16].

A practical tip: request a peer-to-peer review between your prescriber and the plan's medical director before filing a formal appeal. Many denials are reversed at this stage without entering the formal appeals pipeline.

AstraZeneca Savings Programs and Medicare Restrictions

AstraZeneca offers a manufacturer savings card for Farxiga that can reduce out-of-pocket costs to as low as $0 per month for commercially insured patients. Federal law, however, prohibits Medicare beneficiaries from using manufacturer copay cards or coupons [18]. This restriction applies to all federally funded insurance programs, including Medicare Advantage.

There are two alternative pathways for Medicare enrollees who need financial assistance. The AstraZeneca Patient Assistance Foundation (AZ&Me) provides Farxiga at no cost to patients who meet income eligibility criteria, generally those with annual household incomes at or below 400% of the Federal Poverty Level [19]. The application requires documentation of Medicare enrollment, a prescription, and income verification.

Extra Help (Low-Income Subsidy) is a federal program administered by the Social Security Administration. Beneficiaries who qualify pay reduced premiums, deductibles, and copayments for Part D drugs. In 2026, Extra Help eliminates the deductible and caps copays at $4.50 for generic drugs and $11.20 for brand-name drugs for those with incomes below 150% of the Federal Poverty Level [20].

Switching Plans During Open Enrollment to Improve Coverage

Medicare Advantage Open Enrollment runs from October 15 through December 7 each year. If your current plan places Farxiga on a high-cost tier or imposes burdensome step therapy, switching plans is a practical option.

The Medicare Plan Finder tool at medicare.gov allows you to enter your specific medications and compare formulary placement, copay estimates, and total annual drug costs across all available Medicare Advantage plans in your ZIP code. When comparing plans, look beyond the monthly premium. A plan with a $20 higher premium but Tier 3 Farxiga placement could save $1,200 annually compared to a plan with Tier 4 placement and 33% coinsurance.

State Health Insurance Assistance Programs (SHIPs) offer free, unbiased counseling to help Medicare beneficiaries compare plan options. Every state operates a SHIP program, and counselors can run personalized cost comparisons using your complete medication list.

Patients already stable on Farxiga with good clinical outcomes should also consider the Medicare Advantage Open Enrollment Period from January 1 through March 31, which allows a one-time switch to a different Medicare Advantage plan or to Original Medicare with a standalone Part D plan.

Dapagliflozin vs. Empagliflozin: Does Coverage Differ?

Both dapagliflozin (Farxiga) and empagliflozin (Jardiance) are SGLT2 inhibitors with overlapping indications. Medicare Advantage formulary placement often differs between the two based on rebate negotiations rather than clinical evidence. In 2025, approximately 55% of Part D plans placed empagliflozin on a preferred tier over dapagliflozin, while 30% preferred dapagliflozin, and 15% placed both on the same tier [4].

From a clinical perspective, both drugs have strong outcomes data. The EMPA-REG OUTCOME trial (N=7,020) showed empagliflozin reduced cardiovascular death by 38% in patients with type 2 diabetes and established cardiovascular disease [21]. DAPA-HF demonstrated dapagliflozin's 26% reduction in the composite of worsening heart failure or cardiovascular death [7]. The DAPA-CKD trial showed dapagliflozin's 39% reduction in kidney disease progression [9]. Head-to-head trials between the two drugs do not exist.

If your plan covers Jardiance at a lower tier than Farxiga, discuss with your prescriber whether a switch is clinically appropriate. For patients whose primary indication is CKD, dapagliflozin has the more strong kidney-specific trial data from DAPA-CKD, which may support a formulary exception request to obtain Farxiga at a lower cost tier.